Wyeth discounts Pristiq for big sales push

Think the latest-and-greatest drug would naturally be the most expensive? Think again. Now that its Pristiq antidepressant is finally approved, Wyeth is offering a cut-rate price to woo patients over from Effexor XR. And these hip-to-Effexor XR patients might just buy, because Pristiq is essentially a "new-and-improved" version of that drug.

Effexor XR, remember, will be vulnerable to generic competition in 2010--so it behooves Wyeth to switch patients to Pristiq, even at a 20 percent discount off the older antidepressant. And to switch as many as possible, Wyeth plans to make Pristiq the main focus of its primary-care sales force, a Wyeth SVP told Dow Jones.

Of course this pricing tactic is nothing new: Other pharma companies use it, especially now that so many blockbuster drugs are approaching the patent cliff. Seems counterintuitive to undercut your own drug, but unusual times call for unusual measures.

- see the story at the WSJ Health Blog
- check out Pharmalot's coverage

Related Articles:
FDA OKs Wyeth's antidepressant Pristiq
Wyeth's Pristiq shows benefits in clinical trial
FDA issues approvable letter for Pristiq
Wyeth expects provisional OK for Pristiq

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.